Key result
Interatrial shunting represents a potential alternative therapy for refractory heart failure, pending substantiation of beneficial effects by ongoing randomized clinical trials.
Why the study?
Does interatrial shunting improve symptoms and clinical outcomes in patients with refractory heart failure?
Does interatrial shunting improve symptoms and clinical outcomes in patients with refractory heart failure?
Answers are grounded in this paper and cite their sources.
Interatrial shunting is being evaluated as a potential device-based therapy for patients with refractory right or left heart failure.
The creation of an interatrial shunt in order to decompress the right or left atrium in patients with right and left ventricular failure, respectively, has been used as an alternative therapy to improve symptoms and clinical outcomes in patients with pulmonary hypertension-right heart failure and left heart failure refractory to optimal medical therapy. If ongoing randomised clinical trials further substantiate these beneficial effects in patients with chronic HF, interatrial shunting will represent an important new approach for treating this population.
No takes yet. Share an insight, caveat, or question.
Guimarães et al. (2019) conducted a review in Heart failure (right and left ventricular failure). Interatrial shunting was evaluated. Interatrial shunting represents a potential alternative therapy for refractory heart failure, pending substantiation of beneficial effects by ongoing randomized clinical trials.
Synapse has enriched 10 related papers. Consider them for comparative context: